Pulmonary Arterial Hypertension — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
The process of developing an HIV disclosure intervention for youth with perinatally acquired HIV: The HIV Empowering Adults' Decisions to Share - UK/Uganda Project (Heads-Up).
Evangeli Michael et al. — Global public health (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41800659/
- 2.
Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States.
Watzker Anna et al. — Journal of medical economics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41861398/
- 3.
Pulmonary hypertension in dialysis patients: clinical insights from tricuspid regurgitation velocity (TRV)-based echocardiographic criteria.
Koowattanatianchai Sukrisd et al. — Renal failure (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41851998/
- 4.
Smoking exposure on diagnosis and survival of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from REHAP registry.
Khilzi Karys et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41804599/
- 5.
Pulmonary vasomodulators in adults with repaired pulmonary atresia with ventricular septal defect: Single-center experience and review of literature.
Lipps Kirsten M et al. — International journal of cardiology. Congenital heart disease (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41798108/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Recruiting — Phase 2 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT05587712
- 2.
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT07218029
- 3.
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Recruiting — Phase 2 — Pfizer
https://clinicaltrials.gov/study/NCT07073820
- 4.
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Recruiting — Phase 2 — Tectonic Therapeutic
https://clinicaltrials.gov/study/NCT06616974
- 5.
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Recruiting — Phase 1 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT06649110
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a rare, progressive condition causing high blood pressure in the arteries supplying the lungs, leading to right heart failure. It predominantly affects women. While there is no cure, a growing number of targeted therapies can slow progression and improve symptoms.
Most Recent Research
Sharing one's HIV status with others (onward HIV disclosure) for youth with perinatally acquired HIV (PAH) is often difficult but may assist with challenges associated with living with HIV. We describe the development of an intervention to help HIV-sharing decision-making for UK and Ugandan youth with PAH. The methods included : (1) semi-structured interviews with 50 participants (20 with PAH patients aged 18-25 years, 20 friends, family or partners and 10 professionals), (2) a survey of 57 UK participants with PAH patients aged ≥17, (3) the development of an intervention conceptual model, (4) intervention development, including obtaining intervention feedback from 13 youth with PAH. The survey showed that group (23/57; 40%) and mixed individual and group formats (21/57; 37%), mixed gender groups (52/57; 91%) and peer worker involvement (54/57; 95%) were preferred. The interviews highlighted the importance of overcoming feelings of shame and accepting one's status before sharing, having support to feel confident to share, personal values playing a part in sharing decisions and friends and partners explaining that they had not been educated about HIV until someone had shared their status with them. We describe the finalised intervention, and strengths and limitations of the intervention development process are outlined.Trial registration: ISRCTN Registry, ISRCTN31852047, Registered on 21 January 2019.
Common Questions
What is Pulmonary Arterial Hypertension?
Pulmonary arterial hypertension is a rare, progressive condition causing high blood pressure in the arteries supplying the lungs, leading to right heart failure. It predominantly affects women. While there is no cure, a growing number of targeted therapies can slow progression and improve symptoms.
How many clinical trials are available for Pulmonary Arterial Hypertension?
RareWays currently indexes 1086 clinical trials for Pulmonary Arterial Hypertension, of which 190 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Pulmonary Arterial Hypertension come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Pulmonary Arterial Hypertension.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.